An Open-Label Study To Evaluate The Long-Term Safety Of Subcutaneous MOA-728 For Treatment Of Opioid-Induced Constipation In Subjects With Nonmalignant Pain.
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2015
At a glance
- Drugs Methylnaltrexone bromide (Primary)
- Indications Constipation
- Focus Adverse reactions; Registrational
- Sponsors Salix Pharmaceuticals
- 03 Jun 2015 The EC approved RELISTOR (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, according to a Valeant Pharmaceuticals International and Progenics Pharmaceuticals media release.
- 27 Apr 2015 The Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending approval of methylnaltrexone bromide subcutaneous injection (RELISTOR) for the treatment of opioid-induced constipation in adults, according to a Valeant Pharmaceuticals International media release.
- 03 Jun 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).